The QualityStocks Daily Thursday, August 27th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (FPVD) +266.67%

StreetInsider (PED) +41.03%

MarketBeat (AUTO) +34.92%

The QualityStocks Daily Stock List

Amfil Technologies, Inc. (FUNN)

TableTopWire, OTC Markets, Micro Cap Daily, StockNewsUnion, Macroaxis, MMJ Reporter, InvestorsHub, Street Insider, Nasdaq, Stockwatch, GlobeNewswire, Infront Analytics, Morningstar, Insider Financial, Dividend Investor, Stockopedia, Dividend.com, TipRanks, GuruFocus, Investors Hangout, Barchart, wallstreet-online, New Media Wire, and Simply Wall St reported earlier on Amfil Technologies, Inc. (FUNN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Amfil Technologies, Inc. focuses primarily on the acquisition of income generating private companies and optimizing their operations under the Amfil Technologies umbrella. Its emphasis is on growing shareholder value through allowing investors access to self-sustaining small to medium sized businesses with proven profitable strategies, and identified as having substantial potential for future growth. Amfil Technologies is based in Markham, Ontario and lists on the OTC Markets.

The Company chiefly invests in small to mid-sized companies with above average service capacity, growth potential or existing market share. Amfil works to realize long-term financial returns consisting of regular dividend income, benefiting from preferential tax treatment, and expecting modest mid-to-long term capital growth.

Amfil Technologies is the operator of three businesses. One is Snakes & Lattes, Inc. This is a board game bar/cafe and board game retailer/distributor/publisher. Snakes & Lagers and Snakes & Lattes are the operators of board game themed bars and cafes. Snakes & Lagers holds the trade name and is the owner of Snakes & Lattes, which at present operates three tabletop gaming bars and cafes in Toronto and one in Tempe, Arizona. The Company is in the process of expanding throughout North America.

Another Amfil business is the EcoPr03 GRO3 Antimicrobial System. The EcoPr03 GRO3 Antimicrobial System was jointly developed between Amfil Technologies and A.C.T.S., Inc. This system is a triple-function sanitization unit capable of naturally eliminating 99.9 percent of water and airborne pathogens and the typically problematic pests that cause havoc for cultivators, and also bacteria, fungus, microbes, and mold on surfaces, all without chemicals.

Another of Amfil’s businesses is Interloc-Kings Inc. This is a hardscape construction company headquartered in southern Ontario. Interloc-Kings is an established hardscape construction and winter services provider to the Greater Toronto area & York Region, in Ontario. This subsidiary is an authorized Unilock installer. Unilock is North America's premier manufacturer of concrete interlocking paving stones and segmental wall products.

This month, Amfil Technologies announced that its main subsidiary, Snakes & Lattes, Inc., has established a partnership with Canadian retail giant, Loblaws, for the purpose of curating and selling board games on Loblaws’ recently launched online marketplace. This initiative is corresponding with Snakes & Lattes’ push to create a larger and more lucrative e-commerce presence. This new partnership with Loblaws expands the established sales channel via Amazon, and Amfil intends to increase offerings through the Amfil Technologies and Snakes & Lattes websites.

Amfil Technologies, Inc. (FUNN), closed Thursday's trading session at $0.0208, off by 5.4545%, on 754,724 volume with 31 trades. The average volume for the last 3 months is 933,566 and the stock's 52-week low/high is $0.006949999/$0.090899996.

aTyr Pharma, Inc. (LIFE)

Stocktwits, Zacks, Streetwise Reports, DividendMax, Finviz, BioSpace, ChartMill, Morningstar, MacroTrends, Stockhouse, iwatchmarkets, Market Chameleon, MarketBeat, Nasdaq, InvestorsHub, Barchart, MarketWatch, Simply Wall St, YCharts, Proactive Investors, Seeking Alpha, TMXmoney, Market Screener, Investing.com, GlobeNewswire, ETF.com, GuruFocus, Investors Observer, and Stocknews reported earlier on aTyr Pharma, Inc. (LIFE), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A biotherapeutics company, aTyr Pharma, Inc. engages in the discovery and development of unique medicines based on novel immunological pathways. The Company’s research and development (R&D) efforts are centered on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr is translating novel biology into first-in-class therapies with improved patient outcomes. aTyr Pharma has its corporate headquarters in San Diego, California. The Company’s shares trade on the NasdaqGS.

aTyr Pharma has built an international intellectual property (IP) estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. The Company’s chief emphasis is ATYR1923, a clinical-stage product candidate that binds to the neuropilin-2 receptor. The design of it is to down-regulate immune engagement in inflammatory lung diseases.

aTyr Pharma is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs). This is a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and have a high unmet medical need. The Company chose pulmonary sarcoidosis as its first ILD indication. It is presently enrolling a Phase 1b/2a proof-of-concept multi-center, clinical trial.

In response to the COVID-19 pandemic, aTyr Pharma recently initiated a Phase 2 study in patients with COVID-19 related severe respiratory complications. The design of this study is to evaluate the safety and preliminary efficacy of ATYR1923 versus placebo via the assessment of key clinical outcome measures including fever and hypoxia and also inflammatory biomarkers. Moreover, aTyr is advancing its pre-clinical pipeline of tRNA synthetases and NRP2 targeting candidates via internal research efforts, industry, as well as academic collaborations.

Earlier in August, aTyr Pharma announced that its partner, Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kyorin Holdings, Inc., initiated clinical development in Japan for aTyr Pharma’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission. The CTN allows the commencement of clinical development activities in Japan for ATYR1923. The Phase 1 study, to be conducted by Kyorin, will evaluate the safety, pharmacokinetics, and immunogenicity of ATYR1923 in healthy male volunteers in Japan.

Also this month, Dr. Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr Pharma said, “While the advent of the global COVID-19 pandemic impacted our Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis, hindering patient enrollment during the second quarter, I am pleased that the majority of our sites are now continuing enrollment. Due to the strong scientific rationale of ATYR1923’s mechanism of action and its overlap with COVID-19 disease pathology, including inflammatory lung injury, during the second quarter we also initiated a Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications.”

aTyr Pharma, Inc. (LIFE), closed Thursday's trading session at $3.91, off by 10.7306%, on 161,708 volume with 757 trades. The average volume for the last 3 months is 99,863 and the stock's 52-week low/high is $2.13000011/$7.61999988.

Basanite, Inc. (BASA)

Investor Place, Whale Wisdom, Investing.com, Market Wire News, last10k, OTC Markets, Real Investment Advice, Business Insider, Macroaxis, Wallet Investor, TipRanks, Morningstar, Stockwatch, Seeking Alpha, GlobeNewswire, Street Insider, Dividend.com, GuruFocus, Investors Hangout, Simply Wall St, Equities.com, Corporate Information, Stockopedia, Nasdaq, Stockwatch, and Global Banking and Finance reported beforehand on Basanite, Inc. (BASA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Basanite, Inc. wholly owns Basanite Industries LLC, with main interests in the manufacture of concrete reinforcement products made from basalt fiber reinforced polymers. Basanite Industries LLC manufactures BasaFlex™. This is an enhanced basalt rebar. It is engineered to add intrinsic value in a concrete structure through eliminating corrosion problems often associated with intervening products or elements, or naturally caused by the steel reinforcement itself. OTCQB-listed, Basanite, Inc. previously went by the name PayMeOn, Inc. It changed its corporate name to Basanite, Inc. in December of 2018. Established in 2006, the Company is headquartered in Pompano Beach, Florida.

BasaFlex BFRP Rebar benefits include it being stronger and considerably lighter than steel. There is decreased costs for handling and placing. Furthermore, it is 100 percent corrosion resistant. BasaFlex BFRP Rebar eliminates ongoing costs for maintenance and repair. Additionally, it is a sustainable and eco-friendly 100-plus year product.

Moreover, BasaFlex BFRP Rebar has a similar thermal expansion coefficient as concrete. It is a first-rate choice in freeze/thaw environments. BasaFlex BFRP Rebar is also chemical, alkali, as well as UV resistant. It is optimal for use in harsh applications. It is also non-conductive, non-magnetic, and has no RF interference.

Basanite has its BasaMix™ product. It is made up of extremely fine denier Basalt Multifilament Fibers, which are non-corrosive, 3-Dimensional isotropic reinforcement. The Company also has its BasaMesh™ . This is a Geo Grid Material made from Basalt Fiber Reinforced Polymers as an alternative to traditional steel WWM in walls or flatwork, or in other reinforcing applications where coverage depth of application and shadowing are of concern.

This past June, Basanite Industries announced receipt of its initial Certification Test data from the Independent Test Lab at the University of Miami (UM). The Lab concluded that BasaFlex™ Basalt Fiber Reinforced Polymer Rebar (BFRP rebar) was in good standing on the initial test series, having met or surpassed all requirements per ACI440 and FDOT Spec § 932-3 Standards.

The University of Miami’s Certified Test Report [#R-5.10 03-30-20 BASA] details the initial phase of testing protocols and the results. This report indicates that BasaFlex™ outperformed greatly in Tensile Strength tests, surpassing the standard requirements by an average of 42.0 percent across all four sizes of BasaFlex™ tested.

Recently, Basanite Industries announced that it entered into an Exclusive Supplier Agreement with MEP® Consulting Engineers, Inc., to be the exclusive provider of Basalt Fiber Reinforced Polymer (BFRP) Reinforcing Bar (Composite Rebar) and other BFRP products to the Florida-based construction engineering and design community. With this five-year agreement, MEP® (a member of the US Green Building Council) will exclusively utilize Basanite to manufacture and supply BFRP Rebar products, including Basanite's BasaFlex™ and other proprietary products.

Basanite, Inc. (BASA), closed Thursday's trading session at $0.23, off by 6.5041%, on 1,956 volume with 7 trades. The average volume for the last 3 months is 152,189 and the stock's 52-week low/high is $0.076999999/$0.479999989.

FEC Resources, Inc. (FECOF)

Zacks, Wallet Investor, MacroTrends, Pink Investing, hot Stocked, YCharts, Investors Village, Street Insider, 4-Traders, Seeking Alpha, InvestorX, last10k, Nasdaq, Market Screener, PR Newswire, Morningstar, Barchart, Central Charts, Research and Markets, GuruFocus, Macroaxis, Dividend Investor, Stockopedia, VB Profiles, EODData, OTC Markets, Dividend.com, InvestorsHub, TipRanks, Investors Hangout, and Infront Analytics reported previously on FEC Resources, Inc. (FECOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FEC Resources, Inc. engages in the acquisition, exploration, and, when warranted, development of natural resource and mineral properties. The Company is a subsidiary of PXP Energy Corporation (Philex) who holds 54.99 percent of the undiluted issued and outstanding capital of FEC. The primary investment of FEC Resources is a 6.80 percent stake in the United Kingdom (UK) company Forum Energy Limited (FEL).

The Company formerly went by the name Forum Energy Corporation. It changed its name to FEC Resources, Inc. in May of 2005. Incorporated in 1982, FEC Resources has its head office in Vancouver, British, Columbia.

Forum Energy Limited's principal asset is a 70 percent interest in the GSEC101 offshore licence located to the northwest of the Philippine island of Palawan. This area is about 10,360 Km2. It contains the Sampaguita gas discovery that has expected gas in place of 3.4TCF and potential upside to 20 TCF (Trillion Cubic Feet). In additiion, FEC Resources has an investment in a gold exploration project in the Philippines.

FEC Resources also owns 8.46 percent, 12.40 percent, and 19.46 percent interests in the SC 14A Nido, SC 14B Matinloc, and SC 14B-1 North Matinloc situated in the offshore northwest Palawan. It also owns 9.10 percent in SC14C-2; 5.56 percent and 8.18 percent in SC 6A Octon and SC 6B Bonita situated in the offshore northwest Palawan.

Additionally, FEC owns a 100 percent interest in the SC 40 North Cebu, encompassing an area of 340,000 hectares in the northern part of Cebu Island and adjacent offshore areas situated in the Visayan Basin in the central part of the Philippine Archipelago, and also 2.27 percent interest in SC14C-1 Galoc.

This month, FEC Resources announced that it completed its earlier announced Rights Offering on July 31, 2020. The Company received gross proceeds of roughly US$846,750, and converted into equity the Rights Offering Advance of US$170,111 earlier received from PXP Energy.

Excluding the Rights Offering Advance, the net proceeds will be used for repaying in full a working capital loan of US$150,000 due to PXP. FEC has agreed to purchase 6.8 percent of the loan currently due by Forum Energy Ltd. to PXP; this will amount to US$346,202 plus accrued interest. The rest of the net proceeds will be used for general working capital purposes.

FEC Resources, Inc. (FECOF), closed Thursday's trading session at $0.0017, even for the day, on 150 volume. The average volume for the last 3 months is 100,857 and the stock's 52-week low/high is $0.000899999/$0.003959999.

Innovation Pharmaceuticals, Inc. (IPIX)

Stocktwits, Micro Cap Daily, Stock Day Media, StockNewsUnion, Insider Financial, Morningstar, Investing.com, YCharts, Nasdaq, OTC Markets, MarketBeat, Simply Wall St, GuruFocus, News Break, Stockwatch, Stockhouse, Dividend Investor, CRWE World, MarketWatch, Trade Ideas, Dividend.com, InvestorsHub, Wallet Investor, Pharmas Almanac, TradingView, Baystreet.ca, Seeking Alpha, GlobeNewswire, Investors Hangout, and Stockopedia reported earlier on Innovation Pharmaceuticals, Inc. (IPIX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Innovation Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is developing a world-class portfolio of inventive therapies addressing manifold areas of unmet medical need. These include inflammatory diseases, cancer, infectious disease, and dermatologic diseases. The Company previously went by the name Cellceutix Corporation. It changed its name to Innovation Pharmaceuticals, Inc. in June of 2017. Founded in 2007, Innovation Pharmaceuticals is headquartered in Wakefield, Massachusetts. The Company lists on the OTC Markets’ OTCQB.

Innovation’s Brilacidin is a versatile compound with wide-ranging therapeutic potential. It is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints. This includes lessening the incidence of SOM.

The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. In addition, positive results were observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA (Food and Drug Administration)-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection.

Innovation Pharmaceuticals’ Kevetrin is a novel anti-cancer drug. It is shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its important role in controlling cell mutations. Kevetrin has successfully completed a Phase 2 trial in Ovarian Cancer.

This week, Innovation Pharmaceuticals reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based on continuing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be more than 300 in a human lung epithelial cell line. Brilacidin’s SI is higher than the SIs of a vast majority of other antiviral drugs undergoing evaluation as COVID-19 treatments. A high SI means a drug is more likely to be safe and effective in the clinic.

Mr. Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals, said, “The latest Brilacidin in vitro efficacy results against SARS-CoV-2 are outstanding. Selectivity Index is arguably the most important measure to compare the antiviral efficacy between experimental drugs and this new data suggests Brilacidin is in an elite group of anti-coronavirus candidates…”

Innovation Pharmaceuticals, Inc. (IPIX), closed Thursday's trading session at $0.225, off by 0.265957%, on 913,446 volume with 174 trades. The average volume for the last 3 months is 3,475,953 and the stock's 52-week low/high is $0.05/$0.649999976.

R-Three Technologies, Inc. (RRRT)

NetworkNewsWire, MicroCapDaily, StocksCafe, Whale Wisdom, The Hot Penny Stocks, Market Screener, MarketWatch, InvestorsHub, OTC Dynamics, Seeking Alpha, YCharts, Invezz.com, StockInvest.us, Investors Hangout, Morningstar, OTC Markets, Nasdaq, FX Empire, Dividend Investor, TradingView, Investors Observer, TipRanks, PitchBook, Wallet Investor, GuruFocus, Ceo.ca, Barchart, and GlobeNewswire reported beforehand on R-Three Technologies, Inc. (RRRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

R-Three Technologies, Inc. produces an interlocking asphalt brick by recycling asphalt shingles in their entirety. It is the only manufacturer of interlocking products engineered from l00 percent recycled material. The Company’s products are used in different commercial applications. These applications include driveways, patios, pool decks, courtyards, sidewalks, as well as medians. Established in 2007, R-Three Technologies has its corporate headquarters in Caledon, Ontario. The Company’s shares trade on the OTC Markets.

R-Three Technologies has developed technologies designed to recycle used and off-specification asphalt shingles rather than have them deposited in landfills. Regarding its above-mentioned process, the nails are also recovered and sold for scrap. The design of the bricks are to compete favorably with asphalt and concrete in an array of commercial applications.

R-Three Technologies’ product can be pressed into larger sized segments and installed as sound barrier panels, cushioned factory or stable floors and numerous other uses. The Company’s products are lighter and denser than asphalt. Moreover, the product is easier to install than concrete.

A typical 6″ x 12″ x 2″ brick weighs approximately six pounds. This is half the weight of a similar concrete brick. The lighter weight lessens transportation and handling costs. The bricks are non-porous and thus will repel water and oil allowing them to retain their character and appearance. R-Three Technologies states that it will have the ability to produce product in almost any size, shape, and color. Additional end products are being investigated and considered.

Last week, R-Three Technologies, after several years of inactivity, announced that it is taking measures to deliver increased value for shareholders. This is through an improved capital structure and the launch of a number of new, strategic initiatives. As a first initiative, the Company has cancelled $564,000 of debt, as per Company quarterly filing with the OTC.

In addition, R-Three Technologies will shortly be announcing a new restructuring of its equity. Other new measures that aim to boost shareholder value include a new mergers and acquisitions (M&A) strategy and the hiring of a new Senior Management Team to execute these plans.

R-Three Technologies, Inc. (RRRT), closed Thursday's trading session at $0.179, off by 0.555556%, on 365,439 volume with 127 trades. The average volume for the last 3 months is 245,986 and the stock's 52-week low/high is $0.002/$0.324.

Storm Resources Ltd. (SRMLF)

StocksCafe, FinData, BOE Report, Speculating Stocks, moneyhub.net, Street Insider, YCharts, GlobeNewswire, TMXmoney, MarketBeat, Nasdaq, Barchart, Seeking Alpha, Morningstar, Dividend Investor, Macroaxis, TradingView, MarketWatch, Wallet Investor, FX Empire, Dividend.com, Investors Hangout, and Market Screener reported earlier on Storm Resources Ltd. (SRMLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Storm Resources Ltd. operates as a crude oil and natural gas exploration and development company. At present, the Company operates chiefly in northeast British Columbia. Storm has a focused asset base with large land positions in resource plays at Umbach/Nig Creek/Fireweed and the Horn River Basin, both of which have multi-year drilling upside. Storm Resources lists on the OTC Markets. Incorporated in the Province of Alberta on June 8, 2010, the Company has its corporate office in Calgary, Alberta.

Near term, Storm Resources’ efforts are centered on advancing development of the liquids-rich Montney natural gas resource on 172 net sections of land at Umbach, Nig Creek, and Fireweed. The Company’s plan for 2020 in northeast British Columbia is to drill 6-9 horizontal wells (5.0-8.0 net) and complete 8 horizontal wells (7.5 net), with 7 (7.0 net) commencing production this year.

Storm’s estimated capital investment (excluding acquisitions & dispositions) is $52-$60 million. It is forecasting Q4 production of 25,000 to 28,000 Boe/d; and forecasting average annual production of 22,500 to 24,000 Boe/d.

The Company also has its long term plan for the Horn River Basin, in northeast British Columbia. Its land position in the Horn River Basin (shale gas) continues to be a long-term asset that provides major leverage to increased natural gas prices.

Commerciality is proven with one producing horizontal well, and two vertical wells completed and tested. Storm Resources notes that it has no plans for additional activity in the area until there is evidence of a considerable and sustainable increase in natural gas prices.

This month, Storm Resources announced that it filed its unaudited condensed interim consolidated financial statements as at June 30, 2020, and for the three and six months then ended along with the Management’s Discussion and Analysis (MD&A) for the same period. For Q2 2020, Production was 23,935 Boe per day, effectively unchanged from the prior quarter and an increase of 20 percent year over year.

Revenue was $13.86 per Boe. This represents a 33 percent drop from last year primarily because of lower condensate and natural gas prices. Net Loss was $11.7 million; the largest contributor to the decrease from Net Income of $7.9 million last year was an unrealized hedging loss (non-cash) of $13.8 million which represents the change in the value of future hedging contracts.

Storm Resources Ltd. (SRMLF), closed Thursday's trading session at $1.48555, even for the day, on 107 volume with 2 trades. The average volume for the last 3 months is 484 and the stock's 52-week low/high is $0.961000025/$1.48555004.

EQ Energy Drink, Inc. (EQLB)

TipRanks, Stock News Now, InvestingOnline.com, Pennystocks.news, Market Wire News, Invest Tribune, Markets Insider, Stockhouse, Stock Rants, Investors Hangout, PR Newswire, Stockopedia, Wallet Investor, GlobeNewswire and InvestorsHub reported previously on EQ Energy Drink, Inc. (EQLB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

EQ Energy Drink, Inc. (EQ Labs, Inc.) manufactures and distributes energy drink products. The Company has engaged in branding and the packaging redesign of Last Shot® to focus on its innovative formula geared to fitness and wellness. Last Shot® was crafted by first-rate health enthusiasts to help restore the body and mind via proper hydration while fueling one with sustainable energy. EQ Energy Drink, Inc. (EQ Labs, Inc.) has its corporate office in Las Vegas, Nevada. The Company lists on the OTC Markets.

Last Shot ® Premium Hydration Drinks were formulated to help one properly hydrate, replenish, and recover with healthy ingredients that restore the body, while having an appealing taste. Last Shot® contains Vitamin B12, Electrolytes, Milk Thistle, and also low levels of Caffeine. The Company’s featured flavors include Cranberry Raspberry, Lime, Mango, and Pineapple.

Last Shot ® contains Glucorate, which helps remove toxins in the liver. Milk Thistle contains an active ingredient called Silymarin that is an anti-inflammatory and an antioxidant. Caffeine is included to promote sustainability and stimulate mental clarity and wakefulness while energizing the body.

Recently, EQ Energy Drink announced that agreements have been finalized and Last Shot is scheduled to be soon featured on the online marketplace platform "GoVets" (www.govets.com). GoVets is a program sponsored by the National Veterans Small Business Coalition (NVSBC - www.nvsbc.org) designed to make products manufactured and distributed by U.S. military veterans more accessible. GoVets is the only online marketplace where consumers and buyers can access millions of products from thousands of VA-Verified Service Disabled Veteran-Owned Small Businesses (SDVOSB).

EQ Labs Chief Executive Officer, Mr. Mo Owens, said, "We are very excited about Last Shot's new branding and about our relationship with GoVets and are optimistic about future sales and exposure through this unique platform for government and corporate buyers."

EQ Energy Drink, Inc. (EQLB), closed Thursday's trading session at $0.0037, up 32.1429%, on 683,516 volume with 16 trades. The average volume for the last 3 months is 383,954 and the stock's 52-week low/high is $0.000899999/$0.012699999.

Cosmos Holdings, Inc. (COSM)

Proactive Investors, Real Investment Advice, Tech Know Bits, Stockwatch, Stockopedia, and Stockhouse reported previously on Cosmos Holdings, Inc. (COSM), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Cosmos Holdings, Inc. is a global pharmaceutical company headquartered in Chicago, Illinois. The Company specializes in, by way of its subsidiaries, the wholesale of pharmaceutical products throughout Europe. It provides its products to wholesale drug distributors, and wholesalers and retail healthcare providers. Cosmos Holdings lists on the OTC Markets’ OTCQB.

The Company distributes branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical via its trans-European network of more than 160 pharmaceutical wholesale clients and vendors and roughly 400 independent retail pharmacies that extends to 16 countries. These include Germany, the United Kingdom, France, Italy, Poland, the Netherlands, Greece, Hungary, Denmark, Ireland, and Croatia.

Regarding its new nutraceutical brand, Cosmos Holdings released the design and packaging of its first set of dietary supplements on April 19, 2018. These premium supplements feature a sleek design and packaging along with best in class formulation. The first lines of products include Herbal syrups with natural ingredients from Greece, Collagen 24k, Organic Aloe Vera, Hyaluronic, Male & Female Multivitamins, and more.

Specific areas of Company Management's focus include Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Cannabis derived products, and Local & Direct to Pharmacy Wholesale.

Cosmos Holdings’ subsidiaries include Sky Pharm SA. Sky Pharm is based in Thessaloniki, Greece. Sky Pharm trades the excess amounts of approximately 500 medicines that can be exported within the European Union (EU) countries. Another subsidiary is Decahedron Ltd. Decahedron is a pharmaceutical wholesaler incorporated in the United Kingdom (UK) in August of 2011. A third subsidiary is Cosmofarm Pharmaceuticals. Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. Cosmos has entered the nutraceutical market with its own premium brand of food supplements - Sky Premium Life.

Recently, Cosmos Holdings announced its full-year 2018 financial results for the year ended December 31, 2018. 2018 highlights include Revenue improving 23.6 percent to $37 million from $30 million in 2017. Gross Profit increased 23.1 percent to $2.4 million from $1.96 million in 2017. Operating Expenses decreased by 46.7 percent year over year.

Cosmos Holdings, Inc. (COSM), closed Thursday's trading session at $4.39, up 23.662%, on 3,880 volume with 13 trades. The average volume for the last 3 months is 3,346 and the stock's 52-week low/high is $1.14999997/$4.50.

BioVie, Inc. (BIVI)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, Investor Place, Wallmine, Wealth Insider Alert, InvestorsHub, Morningstar, YCharts, EuroInvestor, MarketWatch, GuruFocus, Street Insider, and Simply Wall St reported earlier on BioVie, Inc. (BIVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of unique drug therapies for liver disease. At present,  the clinical-stage Company is centering on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. OTCQB-listed, BioVie has its corporate headquarters in Beverly, Massachusetts.

The Company states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201. 

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States.

BioVie announced in April 2017 that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis. BioVie also announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

The FDA has granted Fast Track designation for BIV201 (continuous infusion terlipressin), BioVie’s patented Orphan drug candidate. BIV201 is currently undergoing evaluation for the treatment of refractory ascites because of liver cirrhosis in a mid-stage (Phase 2a) U.S. clinical trial.

The FDA has granted Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BioVie earlier secured an Orphan Drug designation for terlipressin for treating ascites. The Company is exploring additional Orphan designation opportunities.

Recently, BioVie announced that it completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites because of advanced liver cirrhosis.

Patrick Yeramian, MD, BioVie’s Chief Medical Officer, said, “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications. What we have learned from this initial study is informing our next clinical trial design. The results will be presented to the FDA in the first half of 2019 and we expect to receive guidance on the BIV201 clinical development plan.”

BioVie, Inc. (BIVI), closed Thursday's trading session at $25.00, up 24.9375%, on 4,413 volume with 15 trades. The average volume for the last 3 months is 4,176 and the stock's 52-week low/high is $2.20000004/$34.5400009.

International Frontier Resources Corporation (IFRTF)

Connecting Investor, YCharts, Wallet Investor, GuruFocus, 4-Traders, MarketWatch, Stockhouse, Marketwired, Otc.Watch, Investment Pitch, Investors Hub, Investing News, Market Screener, and Emerging Growth reported earlier on International Frontier Resources Corporation (IFRTF), and today we report on the Company, here at the QualityStocks Daily Newsletter.  

International Frontier Resources Corporation has a demonstrated track record of advancing oil and gas projects. The OTCQB-listed Company, by way of its Mexican subsidiary, Petro Frontera S.A.P.I de CV and strategic joint ventures (JVs) is advancing the development of petroleum and natural gas assets in Mexico.  International Frontier Resources is based in Calgary, Alberta.

International Frontier Resources (IFR) also has projects in the U.S. and Canada. This includes the State of Montana and the Northwest Territories. IFR created a JV company in 2015 - Tonalli Energia - together with Grupo Idesa, one of Mexico’s largest petrochemical companies.  Grupo Idesa is a well-established Mexican petrochemical company.

Block 24 Tecolutla establishes IFR’s Mexican JV as one of the first operators’ in Mexico. In addition, it provides important insights into future rounds. Tecolutla is a very underdeveloped mature field with considerable upside potential.  The Tecolutla Block is in the Tampico-Misantla Basin within the State of Veracruz.

The Tecolutla Field is 7.2 square kilometers. It contains an oil reservoir at 2,340 meters or around 7,700 feet. The Tecolutla Block is a 60-80 m gross pay carbonate reservoir on a structural high with proven oil production.

Tonalli has submitted the regulatory applications and documentation that will allow IFR to go ahead with the drilling permit and operations at Tecolutla. The expectation is that the existing wells at Tecolutla will exceed historic production numbers and peak initial production (IP) rates with the arrival of new recovering techniques, technology, and expertise to be undertaken by Tonalli.

This past November, International Frontier Resources Corporation (IFR) announced that Tonalli Energia, IFR’s JV with Mexican petrochemical leader Grupo IDESA, spudded the first conventional horizontal well, (TEC-11), at its onshore Tecolutla block. TEC-11 is the initial horizontal well in a potential multi-well plan to develop the northern extension of the Tecolutla field that has been identified on Tonalli’s interpretation of the 3D seismic.

Moreover, in December, IFR announced that Tonalli Energia reached total depth at its first conventional horizontal well, (TEC-11), on its onshore Tecolutla block. The TEC-11 field development horizontal well was drilled to a depth of 3283 meters (m) Measured Depth (MD). A total of roughly 670m of measured length of Cretaceous limestone was drilled before the total depth was reached. Oil shows were encountered during drilling.

Furthermore, Tonalli received its first payment from PEMEX for oil shipped from its Tecolutla field. Tonalli’s TEC-10 producing well averaged 156 barrels of oil per day in October and November at an approximate average crude sales price of USD$64.73 per barrel.

International Frontier Resources Corporation (IFRTF), closed Thursday's trading session at $0.01185, up 76.8657%, on 11,000 volume with 2 trades. The average volume for the last 3 months is 19,818 and the stock's 52-week low/high is $0.002799999/$0.021999999.

ReelTime Rentals, Inc. (RLTR)

MarketWatch, Stockhouse, Marketwired, WalletInvestor, Penny Stock Hub, Barchart, Simply Wall St, Penny Stock Tweets, 4-Traders, InvestorsHub, and OTC Markets reported on ReelTime Rentals, Inc. (RLTR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ReelTime Rentals, Inc. (d/b/a ReelTime VR, ReelTime Media Group) is a multimedia publishing business. The Company engages in helping individuals that have been thrust into the public eye to monetize their exposure and control the portrayal of their story. In addition, it develops, produces, and distributes Virtual Reality (VR) Content and technologies under the brand ReelTime VR. ReelTime is headquartered in Seattle, Washington and lists on the OTC Markets.

ReelTime has end to end production, editing, and distribution capabilities for internal and external projects. At present, the Company produces three ongoing series for the Samsung Gear VR platform, VeeR TV, Oculus. It distributes them over manifold VR delivery sites.

Regarding Partnerships, ReelTime partners with other top VR distributors, content producers, and technology providers. Furthermore, concerning its Services, the Company offers Consulting, Production, Monetization, VR Set Design, VR Media Campaigns, as well as VR Content Production.

Pertaining to VR Set Design, ReelTime has a totally-dressed virtual set in its studio facilities. It can create any look one wants for their Virtual Reality show. Also, it can provide traditional virtual set backdrops.

Concerning VR Content Production, ReelTime has a team of editors and other pre/post-production professionals available for all elements of producing VR content. This is from the initial design concepts, to pixel-perfect deliverables.

ReelTime VR announced recently that it became the first to utilize a proprietary technology developed by the Company that allows it to film in full 360 x 360 Virtual Reality formats and simultaneously film in formats compatible with traditional Television platforms. This will allow ReelTime VRs shows the Company produces to not only be available on the rapidly growing premium VR sites it is currently available on, but it will additionally be available for distribution over mainstream Network Television formats and worldwide.

ReelTime has received patent-pending status from the United States Patent and Trademark Office (USPTO) for its non-provisional patent application encompassing apparatus and method claims for technology involving simultaneous capturing of 360 X 360-degree Spherical Panorama Images and Video. The technology will enable any cell phone or other camera to promptly capture 360 X 360 Virtual Reality Video or pictures without any need for stitching.

The VR content is compatible with and can be shared through 360 capable social sites in real time, and on any professional VR platform such as Oculas, Gear VR, Veer VR, Playstation VR, Littlstar, and the HTC Vive.

ReelTime will start using this inventive technology in its production of its award-winning Virtual Reality travel series “In Front of View”. The series commenced filming its second season in Thailand in July. It is shot in English and in Thai. Moreover, ReelTime VR is entertaining licensing agreements with select other VR, film, and TV producers to allow them to also gain a competitive advantage.

ReelTime Rentals, Inc. (RLTR), closed Thursday's trading session at $0.086, up 32.3077%, on 46,980 volume with 7 trades. The average volume for the last 3 months is 104,937 and the stock's 52-week low/high is $0.004499999/$0.094999998.

Force Protection Video Equipment Corp. (FPVD)

AimHighProfits, Promotion Stock Secrets,  and Insider Financial reported  earlier on Force Protection Video Equipment Corp. (FPVD), and today we highlight the Company, here at the QualityStocks Daily Newsletter. 

Force Protection Video Equipment Corp. (Force Protection)  sells high definition (HD) body camera systems and accessories for law enforcement. The Company offers its LE10 Law Enforcement Video Recorder product. Force Protection has its corporate headquarters in Cary, North Carolina.

The Company previously went by the name Enhancer-Your-Reputation.Com, Inc. It changed its name to Force Protection Video Equipment Corp. in March of 2015. 

Force Protection has incorporated a wholly-owned subsidiary, CobraXtreme HD Corp., a North Carolina Corporation. This subsidiary’s purpose is to sell HD videos sports cameras and accessories that are alike to those sold by GoPro. Furthermore, it will sell video goggles and sunglass cameras.

CobraXtremeHD also carries a complete line of aftermarket accessories for extreme sports cameras such as GoPro® and Garmin®. The design of CobraXtremeHD cameras are for use in extreme sports.

Force Protection has its LE50 HD Bodycam. The LE50 is a state-of-the-art designed body camera. It is strategically built around Ambarella chip sets (AMBA). Select important design features of the LE50 include industry leading record time (10 hours @1080,12 hours @720); 50 hours of standby time; 32GB of internal tamperproof storage; and white LED illumination.

Concerning the Company’s LE10 Law Enforcement Video Recorder product, it is a small bodyworn HD camera. It is half the size and half the price of most law enforcement cameras now on the market. The LE10 has manifold features. These include still picture ability 8MP, WIFI, 4x zoom,  and audio recording. The LE10 does not necessitate special software or costly storage contracts.

In addition, Force Protection released the LE100 and LE101 1080 HD in car video recording dashcam systems. The LE100 and 101 are state-of-the-art designed in-car dash camera systems. They are strategically built around Ambarella A7 chip sets (AMBA). 

The Company also has its camera system for Law Enforcement and Security Agencies. The design of the C1, Citadel camera system is to fight and deter graffiti, illegal dumping, and other property crimes. The self-contained system is solar powered.  The C1 Citadel requires no external power. All of Force Protection’s cameras and recording devices have FCC, IC and CE certification.

Recently, Force Protection announced the release of the RECON 1000 on the body camera. The RECON 1000 incorporates into its design the Ambarella A7 chip to ensure its optimal performance for law enforcement officers. The RECON 1000 is a robust IP67 camera. It is small, lightweight and full of standard features that cameras twice its size and price do not include.

Force Protection announced in May that it received patent pending status from the U.S. Patent and Trademark Office (USPTO) for its proprietary design titled: Shield Harness for Mounting a Camera. The newly designed product will permit law enforcement departments to use existing body worn cameras with their riot shields to collect evidence during protests and disturbances and also to document inmate extraction in prisons. The design will enable the cameras to be mounted securely and have an unobstructed view point of individuals for later identification and for training.

Force Protection Video Equipment Corp. (FPVD), closed Thursday's trading session at $0.0011, up 266.6667%, on 278,378,136 volume with 459 trades. The average volume for the last 3 months is 6,524,928 and the stock's 52-week low/high is $0.000000999/$0.001249999.

Yappn Corp. (YPPN)

SmallCapFinancialWire, PennyStocks24, Shiznit Stocks, Stock Shock and Awe, StockRunway, Orbit Stocks, MyBestStockAlerts, Fast Money Alerts, Penny Stock General, TopPennyStockMovers, SmallCapVoice, Information Solutions Group, and Social Hot Dog reported previously on Yappn Corp. (YPPN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Yappn Corp. is a real-time unique language solutions enterprise that amplifies brand messaging, helps conduct commerce, and provides customer support through globalizing these experiences with its proprietary approach to language. Established in 2010, Yappn provides people and brands the power to be social, conduct commerce, and communicate freely without a language barrier.

Yappn has its headquarters in Markham, Ontario. The Company lists on the OTC Markets’ OTCQB. The Company was previously known as Plesk Corp. It changed its name to Yappn Corp. in March of 2013.

In essence, Yappn approaches the challenge of real-time language translation in a completely innovative manner. The result is enhanced translations based on the context of the content or discussion. Consequently, this substantially improves the translation result. According to Common Sense Advisory, more than 72 percent of consumers say they are more likely to purchase online if the experience is in their preferred language.

Backed by its proprietary technology, Yappn’s advanced algorithms return translation with the correct meaning and context of the message. It does so in real-time. The Company’s system is constructed on an enterprise development methodology. It is hosted on Microsoft’s Azure® cloud-based platform.

Yappn provides products for ecommerce, customer care, enhanced messaging collaboration, and online marketing. Furthermore, the Company provides custom translation solutions to different verticals. These include entertainment, retail, as well as marketing.

Yappn has its e-translation product. This is an advanced product that provides global vendors with the ability to integrate into leading ecommerce marketplace sites.

Yappn offers a complete customizable set of tools to engage consumers in more than 100 languages. Yappn is free for users who want to participate on the Company’s general discussion board, unless otherwise noted.

A user’s language is detected by their browser setting automatically. At the very bottom of the page, a user will find a translator bar with the option to choose many languages. A user selects their language and all Yappn pages immediately translate. Everything a person sees on Yappn is in their language, regardless of the language in which it was initially posted.

In May of 2017, Yappn announced that it was granted a new patent for "Cross-Language Communication Between Proximate Mobile Devices" from the Commissioner of Patents representing the Canadian Patent Office. In addition, the patent was also separately granted in the United States on June 9, 2015 as Patent No. US 9,053,097 B2. Canadian Patent No. 2,835,110 was granted on April 11, 2017. It was received by Yappn on May 3, 2017.

Yappn Corp. (YPPN), closed Thursday's trading session at $0.005, up 212.50%, on 370,758 volume with 9 trades. The average volume for the last 3 months is 2,536 and the stock's 52-week low/high is $0.000399999/$0.007.

The QualityStocks Company Corner

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)was featured today in the 420 with CNW by CannabisNewsWire. During the last quarter, California raked in $208.4 million in tax revenue from cannabis. In comparison, this figure was slightly higher when compared with revenue from the first quarter of the year, the CDTFA reported last Wednesday. Despite many industries declining in output or failing, the cannabis market seems to be operating at even greater efficiency, as the report from California shows.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Thursday's trading session at $1.51, off by 3.8217%, on 1,295,429 volume with 3,812 trades. The average volume for the last 3 months is 1,687,130 and the stock's 52-week low/high is $0.400000005/$2.79999995.

Recent News

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)

The QualityStocks Daily Newsletter would like to spotlight LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF).

LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) was featured today in a publication from BioMedWire, examining how, as your drug patent rights lapse, you can lose billions of money as your new competitors enter the market. This is the main reason why several investors always put their concentration on drug patent rights during the evaluation of drug companies. To help you make better investment decisions, here are some of the main factors to put into consideration if you want to invest in drug companies:

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) is a molecular diagnostics company that develops genetic analyzers for rapid detection of pathogens at the point-of-need.

Based in the greater-Boston, Massachusetts area, the company’s fully automated genetic analyzer for pathogen detection, the MiQLabâ„¢, is designed to deliver reference-quality data with ease of use. MiQLab’s technology screens samples for up to 27 different targets at once—looking for pathogens and antimicrobial resistance factors—and returns results in approximately one hour. It is designed to be operated at the site of sample collection to avoid the delay associated with shipping and manually processing samples. This technology is designed for use in multiple markets, including human and veterinary diagnostics, as well as food safety testing ($12.9B, $2.2B, and $23.4B markets, respectively).

Portfolio Benefits

Rapid, automated pathogen detection

LexaGene’s MiQLab pathogen detection system offers rapid and sensitive testing to markets in need of better vigilance against pathogens that could endanger health and harm public safety and the bottom line. The company’s disruptive technology is on-demand and offers results in approximately an hour.

End users collect a sample, load it onto the MiQLab genetic analyzer with a sample preparation cartridge, enter a sample ID and press ‘go’.

MiQLab is open-access, which allows users to easily customize their own tests, in addition to running the company’s own validated tests. No comparable technology exists on the market today for automating customized testing. The open-access market is over $20 billion in value and includes industries like pharma and biotech that currently need an automated method of performing PCR testing in a cost-efficient way.

Improved COVID-19 Testing

As the COVID-19 pandemic continues to pose a threat to global safety, the need for improved testing procedures has been well established. LexaGene’s technology is automated and designed to be used at the point-of-need, thereby avoiding the 12- to 24-hour shipping time. Plus, it performs sample preparation and the gold standard RT-PCR chemistry for exceptional data quality in about one hour.

Because LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens, it is ideally suited to prevent pandemic spread with its easily deployed testing that facilitates rapid quarantine-related decision making.

This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured at specialized production sites – making it impossible to rapidly meet a swift increase in demand.

According to Dr. Jack Regan, LexaGene’s CEO and founder, the world needs easy-to-use, fully automated pathogen detection instruments operating at points-of-need that can be equipped with tests to detect a novel pathogen within a week of knowing its genetic sequence. For this pandemic, the lack of such technology forced the majority of testing to occur in distant reference laboratories, making rapid decisions on quarantine impossible and making the likelihood of successful containment remote.

Regan explained in a press release (http://nnw.fm/Vz5Ju), “LexaGene expects to be the first company to commercialize an automated open-access microfluidic technology designed for use at the point-of-need that can be configured to detect a novel pathogen in just a week’s time of its emergence – for use on-site to return results in one hour – and improve our chances of successful containment.”

Market Potential

LexaGene’s technology has a wide range of applications across many other markets, including biotech and pharma testing, water quality monitoring, agricultural testing, biodefense, and use at point-of-need at border crossings, military bases, aircraft carriers and cruise ships.

Markets for customized testing solutions are poised for significant growth. Industry analysts forecast considerable expansion of many of LexaGene’s potential target markets in the coming years, including:

  • The genotyping sector, forecast to reach a valuation of $31.9 billion by 2023;
  • PCR assays, expected to make up a $7 billion market opportunity by 2026;
  • The sample prep market, forecast to eclipse $9.3 billion by 2025;
  • Water quality monitoring, set to grow to $1.59 billion by 2022; and
  • Agricultural testing, anticipated to reach $6.29 billion by 2022.

LexaGene’s patented microfluidic system was invented by company CEO Regan, a leading scientist who developed a bio-warfare surveillance instrument that has been adopted by the Department of Homeland Security. Regan is also known for developing an instrument that detects respiratory pathogens from nasal swab samples. The development of these instruments was supported by $20 million in government funding.

Management Team

LexaGene’s experienced leadership team drives company growth with a focus on innovation, pursuing unique market opportunities and providing shareholder value.

Dr. Jack Regan, Chief Executive Officer & Director, is the inventor of the company’s flagship automated pathogen detection technology, the MiQLab. Before founding LexaGene, he led a team of scientists at Bio-Rad Laboratories (NYSE: BIO) in developing tests for detecting pathogens, cancer and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Regan helped QuantaLife, a startup company, bring its product from concept to commercialization, where it was subsequently acquired by Bio-Rad. He has also worked at Applied Biosystems/Life Technologies on automated sample preparation and did his post-doctoral training at Lawrence Livermore National Laboratory. His doctoral training at the University of California San Francisco focused on influenza viral replication.

Daryl Rebeck, President, has over 20 years of capital market experience with an established international financial network. Rebeck was a vice president and senior investment advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. He has since worked to provide management expertise and grow shareholder value. He served as senior VP of corporate finance of Auryn Resources (NYSE: AUG), a $250 million market cap mining exploration company.

Jeffrey Mitchell, CFO, boasts over two decades of financial and SEC experience. Before joining LexaGene, he served as controller and director of finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies Inc. In addition to his many years at Palomar, Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging and diagnostic companies.

LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF), closed Thursday's trading session at $0.65712, off by 3.3647%, on 409,702 volume with 126 trades. The average volume for the last 3 months is 377,644 and the stock's 52-week low/high is $0.303799986/$0.928245007.

Recent News

ISW Holdings (ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings (ISWH).

ISW Holdings (OTC: ISWH), a global brand-management portfolio company with diverse partnerships, is entering a promising new space just in time for the revolution in turnkey crypto-mining solutions (http://ccw.fm/SsaTo). A recent article discussing this covers a TradingView report that highlights the company’s opportunity and optimal timing through a recent collaboration it deems a “big deal for ISWH shares.” To view the full article, visit: http://ccw.fm/zEXKJ. Also today, CryptoCurrencyWire released a report highlighting the company which examines the recent news that the recent Q2 ISW Holdings (OTC: ISWH) financial report (http://ccw.fm/O0Riz), which included operational performance data for the three months and six months ended June 30, 2020, “silence(d) the skeptics, with larger than forecast topline growth powered by an expanding home healthcare segment, which could be set to further advance as the company integrates its proprietary telehealth technology into the mix,” noted a recent “Oracle Dispatch” article (http://ccw.fm/ONWIY).

ISW Holdings (ISWH) (“ISW Holdings”) is a brand management portfolio company with diverse partnerships that focus on growing businesses in multiple sectors, including crypto mining, renewable energy, home health care for the chronically ill, wellness and restoration, and the adult beverage industry, as well as early-stage operations in supply chain and logistics management. ISW Holdings operates as the nexus between its partnerships and their essential services for end users.

Mission
The company’s core mission is to enhance these sectors by implementing innovative services and products ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources, and innovative software to establish market-leading companies and partnerships, which ensure their success in their chosen industries. This enables the company to return maximum shareholder value with its focus always on its partnerships’ various sector volatility.

The Revolution
Positioned to create industry leaders, the company’s process entails strategic development and aggressive early growth of its partner brands to establish them as profitable and viable. ISW Holdings’ method is to nurture emerging partner brands through the essential stages of market development (from conceptualization to distribution) in sectors relevant to today’s marketplace. In addition, the company has a holistic approach to business development, with every strategy being delivered person-to-person from developers to end users.

The Challenge
The company’s goal is to turn its target audience into loyal consumers by ensuring transparency and a clear understanding of its products and services, thus creating visibility, credibility, and trust.

ISW Holdings’ Innovative Approach
ISW Holdings has diversified positions in its partnerships across technology, health care, wellness, renewable energy, and the adult beverage sectors. The company seek to provide industry leading modern solutions to its clients and sound business practices to its partners. This is accomplished through an early growth platform that cultivates its partnerships with the necessary resources and expertise to expand exponentially.

ISW Holdings’ Opportunity
The company’s opportunity is considerable. In the ever-changing high demand global marketplace, the need for timely innovation is critical. ISW Holdings’ portfolio brand management and creative thinking has allowed the company to develop and deploy enterprises that meet the needs of 21st century consumers. Through a fully vetted system of scalability, it is able to meet consumer demands with turn-key solutions.

Portfolio of Partnerships and Businesses
ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. With partnerships that incorporate a depth of experience and industry insight, ISW Holdings has established itself as a portfolio company in technology, home health care, and wellness, with a focus on reshaping industry benchmarks.

Bit5ive

ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. As an official distribution partner of Bitmain (the industry’s leading fabless manufacturer of computing chips and distributor of Antminers to more than 30 countries in Latin America, Central America, and the Caribbean), Bit5ive is quickly becoming one of the largest U.S.-based companies in the cryptocurrency mining and bitcoin farm sectors of the market.
Valued at $293.66 million in 2019, the bitcoin technology market is expected to reach $477 million by 2025, according to Mordor Intelligence. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.

Proceso, LLC

With a growing awareness of the importance of renewable energy worldwide, ISW Holdings has partnered with Proceso, LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining – two fields with a typically high energy demand.

Because crypto mining companies mostly operate outside of the United States with higher asset security risks, Proceso will assist these entities in securing their investments by providing a local source of power and infrastructure development. This is aimed at helping to reduce power consumption while creating secure crypto mining data centers in the U.S. For the gaming industry, Proceso is ready to tackle one of its biggest problems, latency, by building next-level infrastructure in key locations.

PHH – Home Health

PHH Paradigm Home Health answers the growing need for homecare services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care. PHH aims to be at the forefront of this change by offering quality care services infused with new emerging technologies.

ISW Holdings’ home health division is currently developing a pilot for on-demand health care, which consists of a dedicated, stable platform for different medical services. The platform will offer greater freedom of choice and transparency by allowing users to find outpatient clinics in their vicinities, compare costs, and pick the most suitable choices. PHH is also developing specialized technology and tools to support health care services outside of the bounds of specialized facilities by focusing on homecare facilities. This can not only shift the burden from hospitals and clinics, but also streamline specific parts of the health care process to enhance service and product distribution.

VOLUM

ISW Holdings’ logistics and supply chain management division was designed with the core goal of increasing supply chain efficiency as one of the key aspects of successfully growing any business. The VOLUM project’s focus is on identifying and then implementing advanced supply chain management strategies and methods that will enable ISW Holdings’ partner companies to scale and grow exponentially. To achieve this goal, the company develops and offers reliable systems and solutions that create innovative technologies and unmanned system operations for overall higher cost-effectiveness.

In the wellness sector, ISW Holdings has opted for a two-pronged approach to create effective, technologically advanced products, as well as developing innovative ways to educate customers about these products. To this end, ISW Holdings has partnered with BioPulse to achieve state-of-the-art research and development and production capabilities, as well as a direct route to market. The company plans to design and launch up to five unique brands in the wellness and restoration sector in 2020.

ISW Holdings is committed to developing product and service innovation in the consumer spirits and adult beverage industry, which faces increasingly strict regulations but growing demand. The company has been a key innovator in the industry for 25 years, having grown successful luxury brands such as Besado Tequila and others. By leveraging its expertise, ISW Holdings can help companies in the adult beverage industry increase production, streamline their supply chains, implement better processes, innovate their marketing strategies, expand into new areas, and build sustainable relationships with partners and customers.

Management Team

Terry Williams, Chief Executive Officer and Director
Terry Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance, and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, Williams amassed considerable corporate experience at United Parcel Service, where he took several logistical roles, including controller, where he managed more than 2,000 employees and a budget of more than $10 billion.

Williams also serves as president of Airwave Transportation and logistics and chief financial officer of AVI Insurance Caribbean, and he has worked in over 37 domestic and international airports. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce, Chairman
Alonzo Pierce is chairman of ISW Holdings and brings a wealth of business development and wealth management experience to the ISW team. He has spent the past 20 years building recognizable brands in multiple industry sectors. He has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands, including selling the world’s only black vodka. He served as regional director for Sapphire Brands, covering the Southwest and Southeast regions. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown, Secretary, Treasurer, Director
Kristina Mahoney-Brown is secretary and treasurer as well as director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings (ISWH), closed Thursday's trading session at $0.124, up 0.404858%, on 52,793 volume with 44 trades. The average volume for the last 3 months is 126,946 and the stock's 52-week low/high is $0.100500002/$5.00.

Recent News

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (OTCQB: SHRMF).

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. To view the full press release, visit http://ibn.fm/upmp5

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

  • Alternative medicine (psilocybin) IP aggregation
  • Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
  • Drafting of benchmark SOPs (Standard Operating Procedures)
  • Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

  • Non-Hallucinogenic Medicines
    • Microdosing Psilocybin/LSD
    • MDMA, commonly known as ecstasy
  • Hallucinogenic Medicines
    • Psilocybin high dose
    • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (OTCQB: SHRMF), closed Thursday's trading session at $0.328, off by 8.8889%, on 589,173 volume with 235 trades. The average volume for the last 3 months is 433,553 and the stock's 52-week low/high is $0.221/$1.74.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/lpsCk). To view the full article, visit: http://ibn.fm/2fWmR

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.15, off by 1.7094%, on 244,400 volume with 518 trades. The average volume for the last 3 months is 971,266 and the stock's 52-week low/high is $1.10000002/$6.25.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, recently announced its plans to participate in investor conferences during the month of September 2020. According to the update, SGLB will participate in the LD 500 Virtual Investor Conference slated to take place from September 1-4, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020. To view the full press release, visit http://nnw.fm/4OjAJ

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Thursday's trading session at $2.51, off by 3.0888%, on 1,636,494 volume with 3,812 trades. The average volume for the last 3 months is 1,410,196 and the stock's 52-week low/high is $1.97000002/$11.6999998.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade Inc. (OTCQB: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has announced that it expects BudCars Cannabis Delivery Service to hit a $650,000 sales milestone in July (http://cnw.fm/g8Jg8). The company also predicts its Q3 2020 sales numbers will top $11 million. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Mexico’s president, Andrés Manuel López Obrador, has stated that the legalization of marijuana will proceed through Congress once it reassembles next month. When asked about a meeting he had with a senator who was pushing for marijuana reform legislation during a press conference last Wednesday, he highlighted the boundaries when it came to the balance and division of powers between the legislative and executive branches of the government. In addition to this, he also stated that the marijuana proposal had existed for quite a while.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Thursday's trading session at $0.00225, off by 2.1739%, on 43,241,060 volume with 168 trades. The average volume for the last 3 months is 68,439,662 and the stock's 52-week low/high is $0.001599999/$0.021999999.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) was featured today in a publication from BioMedWire, examining how you never knew that there would be a pandemic, and you had never seen anything like this before. No one would ever have imagined a thing like this would strike. However, before COVID-19 hit the world, several people had already issued warnings about the pandemic. Those people included medical experts, famous authors, and presidents. These people were issuing warnings in conferences, televisions, and government reports.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprexâ„¢ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprexâ„¢, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprexâ„¢ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprexâ„¢.

Genprex Inc. (NASDAQ: GNPX), closed Thursday's trading session at $3.92, up 1.5544%, on 1,019,667 volume with 3,446 trades. The average volume for the last 3 months is 1,796,981 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF), a B2B global vendor of next-generation, push-to-talk over cellular (“PTT”) devices and cellular booster systems, will be participating at the upcoming LD 500 Virtual Conference. The four-day gathering, slated for Sept. 1–4, 2020, and featuring some of the most prominent companies in the micro-cap world, is the most ambitious event yet for the LD event group. To view the full press release, visit http://nnw.fm/f7Qbs

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Thursday's trading session at $0.085, up 6.25%, on 63,800 volume with 12 trades. The average volume for the last 3 months is 168,103 and the stock's 52-week low/high is $0.061999998/$0.356400012.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Thursday's trading session at $16.65, up 0.909091%, on 65,428 volume with 514 trades. The average volume for the last 3 months is 251,524 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Thursday's trading session at $5.65, up 1.9856%, on 33,333 volume with 229 trades. The average volume for the last 3 months is 53,681 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Thursday's trading session at $1.35, up 8.00%, on 8,303 volume with 31 trades. The stock's 52-week low/high is $0.05/$2.4999001.

Recent News

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

  • The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
  • In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
  • The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Thursday's trading session at $0.15, up 7.1429%, on 307,810 volume with 60 trades. The average volume for the last 3 months is 237,535 and the stock's 52-week low/high is $0.047449998/$0.209999993.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Thursday's trading session at $0.55, up 10.1101%, on 213,790 volume with 113 trades. The average volume for the last 3 months is 314,592 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.